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Various reports suggest that 30 to 50% of women in the reproductive age 
group suffer from excessive and irregular uterine bleeding by various 
causative factors. Various treatments prescribed in modern medicine like 
hormone therapy, antiprostaglandins and antifibrinolytic agents etc have 
not proved their definite efficacy inspite of high price and side effect, and 
lastly hysterectomy may lead to hormonal imbalance and psychological 
upset in young fertile women. Ayurveda considered the same as Asrigdara 
and Stambhana Chikitsa is the commonly prescribed management for this. 
But prior to Stambhana Chikitsa, Pachana Chikitsa is to be performed as 
without Amapachana, Stambhana Chikitsamay not show better efficacy. So a 
clinical trial was conducted on 30 Patients, who were divided in 2 groups, 15 
patients in each. In Group A (Control group) Stambhana Chikitsa alone with 
Panchavalkala Kashaya was given and in Group B (Trial group) Stambhana 
Chikitsawith Panchavalkala Kashaya proceeded by Pachana Chikitsa with 
Guduchyadi Kashaya was given to patients for treatment. The present Study 
reveals, significant benefit in trial group to reduce symptoms of Asrigdara 
with a p-value of <0.001 in comparison with alone Stambhana Chikitsa. 
 
INTRODUCTION
Asrigdara is a condition with abnormally heavy 
or prolonged cyclic/ acyclic menstrual period. This 
disease can be better understood with condition 
Abnormal Uterine Bleeding (AUB) in terminology. This 
disease state constitutes of blood loss greater than 80ml 
and/or menstrual period longer than 7 days. AUB affects 
30- 50% of women in reproductive age and a leading 
cause (50- 70%) for the women who get hysterectomy 
before the age of 60 years. In most of cases 
(approximately 50%), no organic pathology is evident 
and DUB (Dysfunctional uterine bleeding) is diagnosed. 
The Pachana is the procedure to resolve the Ama at 
various elements i.e. Kostha, Dosha, Dhatu level. It is a 
special method of Langhana which is in turn one among 
Shadupakrama and part of Apatarpana Chikitsa. Pachana 
Oushadhi is indicated in initial stages of many disorders 
including Jwara and Raktapitta etc. The Chikitsa of 
Asrigdara adopts core concepts of Rakta Pittahara 
Chikitsa. Acharya Charaka clearly states that Stambhana 
Chikitsa is not advocated when Shonita is Dushta and 
patient is strong enough to sustain the bleeding. He made 
more stress in the role of Ama while treating Rakta Pitta. 
As Amata of the Pitta augment the Rakta Pitta, Dosha 
Pachana has specific role in its management. Pachana is 
considered as one of the Shamanarupa Langhana as the 
part of Shadupakrama. Aim of the present study is to 
evaluate the action of Pachana Chikitsa on Rakta Pradara 
disease. Here Guduchyadi Kashaya and Pancha Valkala 
Kashaya were chosen in Rakta Pradara disease for 
present study. Guduchyadi Kashaya contains Tikta Rasa 
Pradhana Dravyas, so they pacify the Ama of Pitta Dosha 
and Pancha Valkala Kashaya contains the Stambhana 
Dravyas which stops the flow of excessive bleeding per 
vagina. 
Nidana of Asrigdara 
 Lavana & Amla Rasa both have predominance of 
Jala, Tejo Mahabhuta. Jala Mahabhuta increases the Drava 
Guna & Tejo Mahabhuta increases Pitta because of Ushna 
Guna. These increased Ushna with increased Dravata leads 
to Sama Pitta. Over intake of Snigdha, Krushara, Payasa, 
Gramya, Audaka Mamsa together Medo Vridhikara 
substances are generally of Guru property. Snigdha and 
Guru properties enhance the Dravamsha in the body. 
When these are associated with remaining Pittavardhaka 
Dravyas, the Dravamsha of Pitta also enhances, thus 
making the Pitta, ‘Sama’[1]. Atimatrasana is given in both 
Charaka Samhita and Ashtanga Samgraha which means 
Atimatrashana is the chief causative factor for 
Amapradosha[2]. Ajeerna, Abhojana, Atibhojana, 
Atimatrasana, Vishamasana will cause Ama[3]. 
Samprapti 
Samprapti is the process of the manifestation of 
the disease. The procedure in which the Doshas get 
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vitiated and the way in which they manifest the disease 
is called Samprapti or Jati or Agati. A good understanding 
of it is very essential for early diagnosis, prognosis and 
for adopting preventive and curative measures. The 
woman who partakes the Hetu enlisted earlier, her 
aggravated Vayu withholding the Rakta being 
accompanied by Rasa vitiated due to the Nidanasevana 
carries it to the uterine vessels and increases the amount 
of Raja. The Pitta, which is aggravated due to its Nidana 
factors is propelled by Vata into the Rakta Dhatu. As 
Rakta is the yoni for Pitta, the quantity of Rakta increases 
in amount[4]. The Ushma, the quality of Pitta or Rakta 
which is excess at this stage, makes all the other Dhatus 
to secrete more Drava. Rasa which is also increased due 
to its own Nidana factors also contain more Drava which 
also is secreted by the Ushma. This secreted Drava enters 
into the Rakta which vitiates the quality of Rakta. This 
Drava is nothing but the ‘Samatva’ of Pitta. As the Gunas 
of Rakta are vitiated, so the characters of Rakta also get 
vitiated. Hence, Suddha Artava Lakshanas which must be 
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Lakshana (symptoms) 
The phase of Purvarupa of the Asrigdara is not 
mentioned in the texts. (probably there may not be any 
premonitory symptoms). The Samprapti of Asrigdara is 
completed by Dosha- Dushya, Sammurchhana and 
Sthanasamsraya. The vitiated Dosha create various 
Lakshanas which are Sthanika as well as Sarvadaihika of 
Asrigdara[5]. Acharya Charaka has described the only one 
symptom i.e. presence of excessive bleeding during 
menstruation. According to Sushruta, when same 
menstruation comes in excess amount for prolonged 
period even without normal period of menstruation, 
different from the features of normal menstrual blood or 
denoting the features of specific Dosha known as 
Asrigdara[6]. All types of Asrigdaras are associated with 
body ache and pain[7]. 
Significance of present study- Pachana & Stambhana 
 Asrigdara Chikitsa resembles and adopts core 
concepts of Rakta Pittahara Chikitsa. It is said that in all 
kinds of Pradara, the management principles of 
Raktatisara, Raktapitta and Raktarshas are to be 
adopted[8]. The reason behind this indication is again the 
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concept of, Pittanubandhatva, Rakta Dushyatva, Nidana 
Samyatvam are the factors found commonly in both the 
above conditions[9]. 
Role of Stambhana 
 It is not necessary to stress the importance of 
Stambhana in Asrigdara, as it is very sure that Rakta is 
“Jeevana”; its excess flow certainly kills the patient just 
like the fire which burns the heap of straw within no 
time. Raktapradara, just like Raktapitta and Atisarais a 
Sroto Atipravrittijanya Vyadhi. Stambhana is the Karma 
which stops the Atipravritti (stambhanamstambhayatiya-
tgatimantam). Hence, Stambhana Karmahas a major role 
in all these conditions. Kashaya Rasa is having best 
Stambhana property and Stambhana is the basic 
treatment principle in Srava Pradhana disorders 
particularly in Asrigdara. 
Role of Pachana 
 Acharya Charaka clearly mentions in the 
management of Raktapitta not to perform Stambhana 
Chikitsa when the Shonita is Dusta and patient is having 
enough strength and power and is taking food in 
sufficient quantity. He stresses on the role of Ama while 
treating Raktapitta. As Amatva in the Pitta delays the 
healing time of Raktapitta, so the Dosha Pachana has 
specific role in its management[10]. Further Acharya 
Charaka explains the role of Tikta Rasa in Rakta 
Samgrahana and Dosha Pachana while treating 
Raktapitta[11]. Here the Tikta Rasa is used as a Pachaka 
particularly Dosha Pachaka of Pitta. The Tikta Rasa 
possesses Laghu, Ruksha Guna which antagonizes the 
increased Drava Guna and Guru Guna of Pitta. Vayu – 
Akasha Guna Bhavas of  Tikta Rasa improve the quantity 
of Pitta and Raktavaha Srotas. Thus, this helps in 
Skandana Kriya which is deranged in Raktapitta as well 
as Raktapradara. Hence, Pachana Karma with Tikta Rasa 
in Raktapitta & Raktapradara is very crucial particularly 
when Ama Lakshanas are found at Doshic level. 
Stambhana works very effectively when Doshas are in 
Nirama state. Hence, Pachana followed by Stambhana 
certainly provides a great cure in Raktapradara disease. 
Materials and Methods 
Plan of study 
 30 patients of Raktapradara were selected on 
random basis from OPD & IPD of Sri Venkateswara 
Ayurvedic College & Hospital, Tirupati with the 
complaints of Rakta Pradara for the present study. Study 
was approved by Institutional Ethics Committee with 
approval no. IEC SVAYC/131908005. 
Method of Research 
The method adopted in present study was 
Randomised open labelled comparative clinical trial 
before and after the treatment. 
Table 1: Details of Group A &Group B 
Group Group-A Group-B 
Drug Panchavalkala Kwatha Churnam Guduchyadi Kwatha Churnam followed 
by Pancha Valkala Kwatha Churnam 
Duration  15 days 15 days + 15 days 
Route of administration Oral Oral 
Form  Kashaya Kashaya 
Kala 2 times Abhaktam 2 times Abhaktam 
No.of pts 15 15 
Ingredients  
Guduchyadi Kwatha Churna-Guduchi, Nimba, Dhanyaka, 
Chandana, Padmaka[12]. 
Panchavalkala Kwatha Churnam-Vata, Udumbara, 
Asvatha, Parisha, Plaksha[13]. 
Method of Preparation of the Drug 
Guduchyadi Kwatha Churna was prepared in 
Srinivasa Mangapuram Ayurveda Pharmacy of 
S.V.Ayurvedic College, Tirupati. First Guduchi, Nimba, 
Padmaka, Dhanyaka, Rakta Chandana Kwatha Churnas 
were prepared separately; some residue is discarded and 
then mixed together by mixing machine. The Kwatha 
Churna was provided to the patient and they were 
advised to prepare Kashaya by themselves. 
Inclusion Criteria 
1. Excessive bleeding during menstruation [change of 
more than 3 soiled pads in a day or depending on 
patients complaints] for more than 2 consecutive 
cycles. 
2. Prolonged menstrual bleeding (> 5 days). 
3. Passing of large clots. 
4. Short intervals of menstrual cycle < 25 days. 
5. Cases of functionally abnormal menstrual cycles only 
will be selected. 
6. Age between menarche and menopause. 
Exclusion Criteria 
1. Intrauterine growths such as Myoma, Endometrial 
Polyp etc. 
2. Cancer of cervix and or uterus. 
3. Tumours or cysts of ovary. 
4. Any other systemic disorders likely to influence 
menstrual cycle. Eg: Diabetic etc.  
5. Case undergoing treatment for any other serious 
illness. 
6. Woman using an IUCD or OCP. 
7. Veneral disease. 
8. Patients with Ksheena Bala, Mamsa. 
9. Excessive bleeding in post menopausal women. 
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Lab Investigations 
 Following laboratory investigations were carried out 
in each patient before& after treatment. 
 HB, TC, DC, ESR, CT, BT. 
 If necessary USG, Thyroid profile, Pap smear, 




 Various demographic parameters viz. Age, 
Marital Status, Religion, Nature of work etc. along with 
specific features of Prakriti, Satva, Samhanana etc. were 
analyzed in the present clinical trial. 
Subjective Assessment 
 The patients undergone treatment were 
assessed for efficacy of Guduchyadi Kwatha on the basis 
of grading criteria depicted below for improvement in 
specific symptomatology of Rakta Pradara.  
Statistical Analysis 
 The effect of therapy has been presented here, 
with the help of paired ‘t’ test & un paired ‘t’ test. Graph 
Pad in Stat Software used for statistical analysis. 
Presentation of Data 
The data collected & analyzed has been depicted in the 
following sequence: 
 General observations viz. age, sex, religion etc. 
 Results of therapy evaluated on the basis of 
improvement in symptomatology. 
Observations and Results 
Criteria for Grading 
 A special grading had been given to Bleeding 
Amount, Duration of bleeding, Interval of Menstruation, 
Passage of clots, Pain (pain in Abdomen/ Backache), 
Burning Sensation (Daha), Weakness (Dourbalya), 
Angamarda, Bhrama, Pandutva (pallor), Trishna, Jvara, 
Swasa, Aruchi from 0 to 3 depending upon the severity. 
E.g: duration of bleeding: 3-5 days-grade0; 6-7 days-
grade1; 8-9 days-grade2; 9& above-grade3. 
Statistical analysis 
The obtained information was analyzed 
statistically in terms of mean score(x), Standard 
Deviation (S.D.), Standard Error (S.E.). Paired t-Test was 
carried out at the level of 0.05, 0.01, and 0.001 of P levels. 
For the more effectiveness of therapy paired t-Test is 
carried out. The results were interpreted as 
P > 0.05 Insignificant 
P < 0.05 Significant  
P < 0.01 Highly significant 
P< 0.0001 Extremely Significant 
Effect of therapy 
Table 2: Effect of drug on subjective parameters in Group A 
Symptoms B.T. A.T. % Relief Mean S.D. S.E. ‘t’ P 
Bleeding amount 2.26 1.13 50 1.133 0.6399 0.1652 6.859 <0.0001 
Duration of bleeding 2.2 0.86 60.9 1.33 0.6172 0.1594 8.367 <0.0001 
Interval of menstruation 2.066 0.93 54.98 1.133 0.7432 0.1919 5.906 <0.0001 
Passage of clots 2.2 0.86 60.9 1.33 0.6172 0.1594 8.367 <0.0001 
Pain 1.866 0.66 64.6 1.20 0.6761 0.1746 6.874 <0.0001 
Burning sensation 1.6 0.73 54.37 0.866 0.5164 0.133 6.500 <0.0001 
Weakness 1.533 0.6 60.86 0.933 0.5936 0.1533 6.089 <0.0001 
The initial mean of bleeding amount was 2.26, which reduced to 1.13 showing 50% relief, which was 
statistically highly significant (p< 0.0001). The initial mean of duration of bleeding was 2.2, which reduced to 0.86 
showing 60.9% relief, which was statistically highly significant (p< 0.0001). The initial mean of interval of 
menstruation was 2.06, which reduced to 0.93 showing 54.98% relief, which was statistically highly significant (p< 
0.0001). The initial mean of passage of clots was 2.2, which reduced to 0.86 showing 60.9% relief, which was 
statistically highly significant (p< 0.0001). The initial mean of pain was 1.86, which reduced to 0.66 showing 64.6% 
relief, which was statistically highly significant (p< 0.0001). The initial mean of burning sensation was 1.6, which 
reduced to 0.73 showing 54.37% relief, which was statistically highly significant (p< 0.0001). The initial mean of 
weakness was 1.533, which reduced to 0.6 showing 60.86% relief, which was statistically highly significant (p< 
0.0001). 
Table No: 3: Effect of drug on subjective parameters in Group B 
Symptoms B.T. A.T. % Relief Mean S.D. S.E. ‘t’ P 
Bleeding amount 2.4 0.4 83.3 2.00 0.5345 0.1380 14.49 <0.0001 
Duration of bleeding 2.466 0.4 83.77 2.067 0.5936 0.1533 13.48 <0.0001 
Interval of menstruation 2.4 0.26 89.16 2.133 0.8338 0.2153 9.909 <0.0001 
Passage of clots 2.466 0.4 83.77 2.067 0.5936 0.1533 13.48 <0.0001 
Pain 2.26 0.33 85.39 1.933 0.7988 0.2063 9.374 <0.0001 
Burning sensation 1.933 0.33 82.9 1.600 0.8281 0.2138 7.483 <0.0001 
Weakness 2 0.4 80 1.600 0.7368 0.1902 8.411 <0.0001 
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The initial mean of bleeding amount was 2.4, which reduced to 0.4 showing 83.3% relief, which was 
statistically highly significant (p< 0.0001). The initial mean of duration of bleeding was 2.46, which reduced to 0.4 
showing 83.77% relief, which was statistically highly significant (p< 0.0001). The initial mean of interval of 
menstruation was 2.4, which reduced to 0.26 showing 89.16% relief, which was statistically highly significant (p< 
0.0001). The initial mean of passage of clots was 2.46, which reduced to 0.4 showing 83.77% relief, which was 
statistically highly significant (p< 0.0001). The initial mean of pain was 2.26, which reduced to 0.33 showing 85.39% 
relief, which was statistically highly significant (p< 0.0001). The initial mean of burning sensation was 1.933, which 
reduced to 0.33 showing 82.9% relief, which was statistically highly significant (p< 0.0001). The initial mean of 
weakness was 2, which reduced to 0.4 showing 80% relief, which was statistically highly significant (p< 0.0001). 
Table 4: Showing percentage of relief comparison between Group A & Group B on subjective criteria 
Sl.No. Symptoms Group A % of relief Group B % of relief 
1 Bleeding amount 50 83.3 
2 Duration of bleeding 60.9 83.77 
3 Interval of menstruation 54.98 89.16 
4 Passage of clots 60.9 83.77 
5 Pain 64.6 85.39 
6 Burning sensation 54.37 82.9 
7 Weakness 60.86 80 
Table 5: Unpaired ‘t’ test for Group A & Group B 
Symptom  Mean A Mean B Diff b/n Means ‘t’ value P 
Bleeding amount 1.133±0.1652 2.000±0.1380 0.8667±0.2153 4.026 0.0004 (<0.01) 
Duration of bleeding 1.333±0.1594 2.067±0.1533 0.733±0.2211 3.317 0.0025 (<0.01) 
Interval of menstruation 1.133±0.1919 2.133±0.2153 1.000±0.2884 3.467 0.0017 (<0.01) 
Passage of clots 1.333±0.1594 2.067±0.1533 0.733±0.2211 3.317 0.0025 (<0.01) 
Pain  1.200±0.1746 1.933±0.2063 0.733±0.2702 2.714 0.0114 (<0.05) 
Burning sensation  0.8667±0.133 1.600±0.2138 0.733±0.2520 2.910 0.0078 (<0.01) 
Weakness 0.933±0.1533 1.600±0.1902 0.6667±0.2443 2.729 0.0111 (<0.05) 
Table 6: Effect of drug on associated complaints in Group A 
Symptoms No  B.T. A.T. % Relief Mean  S.D. S.E. ‘t’  P 
Angamarda 13 1.77 0.88 50 0.88 0.33 0.11 8.00 <0.001 
Bhrama 10 1.00 0.14 85.71 0.85 0.37 0.14 6.00 <0.001 
Panduta 9 1.16 1.00 14.28 0.16 0.40 0.16 1.00 >0.05 
Trishna 8 1.60 0.80 50 0.80 0.44 0.20 4.00 <0.05 
Jvara 12 1.14 0.42 62.50 0.71 0.48 0.18 3.84 <0.05 
Shwasa 4 1.33 0.66 50 0.66 0.57 0.33 2.00 >0.05 
Aruchi 7 1.44 0.55 61.53 0.88 0.33 0.11 8.00 <0.001 
The above table showing statistically highly significant relief in Angamarda, Bhrama, Aruchi, while significant relief in 
Trishna, Jvara and non- significant relief in Panduta and Shwasa. 
Table 7: Effect of drug on associated complaints in Group B 
Symptoms No B.T. A.T. % Relief Mean S.D. S.E. ‘t’ P 
Angamarda 14 2.20 0.70 68.18 1.50 0.52 0.16 9.00 <0.001 
Bhrama 10 1.00 0.14 85.71 0.85 0.37 0.14 6.00 <0.001 
Panduta 9 1.85 1.14 38.46 0.71 0.48 0.18 1.00 <0.05 
Trishna 10 1.25 1.12 90 1.85 0.35 0.12 4.00 <0.001 
Jvara 9 1.85 0.28 84.61 1.57 0.53 0.20 3.84 <0.001 
Shwasa 4 1.50 0.75 50 0.75 0.50 0.25 2.00 >0.05 
Aruchi 8 1.50 0.50 66.66 1.00 0.63 0.25 8.00 <0.05 
The above table showing statistically highly significant relief in Angamarda, Bhrama, Trishna, Jvara, while significant 
relief in Panduta, Aruchi and non significant relief in Shwasa. 
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Table 8: Effect of drug on hematological investigations in Group A& Group B 
 B.T. A.T. % Relief Mean S.D. S.E. ‘t’ P 
 
HB 
Group A 11.36 11.14 1.93 0.22 1.38 0.44 0.50 > 0.05 
Group B 10.43 11.31 8.44 0.88 1.06 0.32 2.74 < 0.05 
 
BT 
Group A 2.59 2.49 4.63 0.12 0.12 0.038 0.037 > 0.05 
Group B 2.51 2.26 8.49 0.21 0.30 0.09 2.33 < 0.05 
 
CT 
Group A 5.20 4.92 4.32 0.22 0.45 0.14 1.56 > 0.05 
Group B 4.81 4.47 9.43 0.45 0.74 0.22 2.02 > 0.05 
Group A shows statistically non significant result& Group B shows statistically significant result in increased HB and 
decreased BT. 
Table 9: Overall assessment of result in Group A& Group B( Paired ‘t’ test) 
 B.T. A.T. % Relief Mean S.D. S.E. ‘t’ P 
Group A 11.533 4.933 57.2 6.600 1.920 0.4957 13.31 <0.0001 
Group B 13.466 2.133 84.16 11.33 2.440 0.6299 17.99 <0.0001 
Table 10: Un paired ‘t’ test for overall result 
 Mean A Mean B Diff b/n mean A&B ‘t’ P 
All symptoms 6.600±0.4957 11.33±0.6299 4.733±0.8016 5.905 <0.0001 
Table 11: Showing the overall Assessment of Clinical trial 
 
Result 
Group A Group B 
No of pts % No of pts % 
Cured 1 6.66% 13 86.6% 
Markedly improved 7 46.6% 2 13.3% 
Improved 7 46.6% 0 0 
No improvement 0 0% 0 0% 
 The therapy had complete relief for 86.6 % of 
patients in Group B& 6.66% relief in Group A. So 
comparatively Group B is better than Group A. 
Discussion on data of disease 
Effect of therapy on specific clinical features 
 In Group-B better improvement was found in the 
symptom of Bleeding amount i.e. 83.3% while in Group-
A, it shows 50 % improvement in the same symptom. 
83.77% relief was found in the symptom of Duration of 
bleeding in Group-B while only 60.9 % relief was found 
in Group-A. Statistically highly significant relief of 89.16 
% (p<0.0008), was observed in inter menstrual bleeding. 
Best improvement 85.39%, 82.9 % and 80% were found 
in the symptoms of pain, burning sensation, weakness in 
Group-B and 64.6 %, 54.37% and 60.86 % improvement 
were found in the same symptoms of Group-A 
respectively. 83.77% relief was found in the symptom of 
passage of clots in Group-B while only 60.9 % relief was 
found in Group-A. Statistically highly significant relief 
(p<0.0001) was observed on bleeding amount, duration 
of bleeding, inter menstrual bleeding, passage of clots, 
Pain, burning sensation and weakness in both groups. 
However, as per percentage wise comparison Group-B 
shows better result than Group-A. 
Effect of therapy on associated complaints 
In Angamarda 68.18% relief was observed in 
Group-B and 50% in Group-A. The result was highly 
significant in both groups. In Bhrama 85.71% relief was 
observed in the both groups. The result was highly 
significant in both the groups. In Panduta 38.46% relief 
was observed in Group-B and 14.28% in Group-A. The 
result was significant in Group-B. In Trushna 90% relief 
was observed in Group-B and 50% in Group-A. The result 
was highly significant in Group-B and significant in 
Group-A. In Jwara 84.61% relief was observed in Group-
B and 62.50 in Group-A. The result was highly significant 
in Group-B and not significant in Group-A. In Shwasa50% 
relief was observed in both groups. Non significant result 
was found in both groups. In Aruchi 66.66% relief was 
observed in Group-B and 61.53% in Group-A. The result 
was highly significant in Group-A and significant in 
Group-B. 
General symptoms of Raktapradara showed a 
maximum number of patients complained Katisula, 
Angamarda, Daurbalya etc. The major reason for the 
manifestation of Kati Sula may be the active involvement 
of Apanavayu. Because the location of the Vayu is mainly 
in this region. Moreover, the vaginal discharge was also 
due to the active involvement of the Apana Vayu. Both 
the site and actions were interconnected with the 
Apanavayu. Angamarda may be the result of vitiated 
Vayu. Dourbalya may be due to Dhatu Kshaya. Rakta, 
which provides Jivana to the body, is being lost in this 
disease. It results in enhanced Vata due to Dhatu Kshaya. 
Effect of therapy on hematological investigations 
 Hb level was 8.44% increased and the result was 
significant in Group-B while non-significant result was 
found in Group-A. Bleeding time was decreased 8.49% in 
Group-B and 4.63% in Group-A. The result was 
significant in Group-B. Clotting time showing non- 
significant result in both groups. 
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Discussion on mode of action of drug 
 In the present study the drug Guduchyadi 
Kashaya is selected for Ama Pachana of Pitta Dosha 
followed by Panchavalkala Kashaya for Stambhana in 
Nirama Asrigdara. Guduchyadi Kashaya is having Tikta 
Rasa, Ushna Virya and Laghu property which decreases 
Dravata of Samapitta which helps in Ama Pachana. 
Pachana Dravya will act as a Shamana Oushadi too. The 
ingredients of Panchavalkala Kwatha Churna are mainly 
Kashaya Rasa Pradhana. As the Kashaya Rasa having best 
Stambhana property and Stambhana is the basic 
treatment principle in Srava Pradhana disorders.  
Overall effect of therapy 
 Total cure was observed in 6.66% of patients of 
Group A, where as in Group-B it is 86.6%. Marked 
Improvement was observed in 46.6% patients of Group-
A where as in Group-B it is 13.3%. In remaining patients 
of Group A (46.6%) improvement was observed. So, 
group-B that is Pachana followed by Stambhana is 
showing better results than group-A that is only 
Stambhana group. 
CONCLUSION 
 After scrutinizing the study regarding Asrigdara 
and its management following conclusions can be drawn. 
Asrigdara mentioned in Sama Raktaja Vikaras. Ama is an 
important factor in production of different diseases. If a 
disease is produced from Ama, then first step of 
treatment should always be the management of Ama. To 
make the condition Nirama, one has to adopt Langhana 
procedure for ‘Ama Nirharana’. Pachana is indicated in 
different diseases during the period when they are 
associated with Ama. Pachana consists of Agni & Vayu 
Mahabhuta. Agni has the Vilayana property where as 
Vayu has Soshana property. As a combination, Pachana 
causes Ama Nirharana from the body. Stambhana is the 
basic treatment principle in Srava Pradhana disorders. 
The drug Guduchyadi Kashaya is selected for Ama 
Pachana of Pitta Dosha as treated drug followed by 
Panchavalkala Kashaya for Stambhana in Nirama 
Asrigdara. The present clinical data shows that, there is 
statistically significant improvement (P<0.0001) with 
regard to the percentage of improvement in results and 
also the relief given by the treatment (Total cure was 
observed in 6.66% of patients of Group A, where as in 
Group-B it is 86.6%). By this it could be concluded that 
Pachana group is effective in reducing the severity of the 
disease. It can be concluded that there is satisfying scope 
of suggesting this Ayurvedic management as safe and 
effective procedure for Asrigdara. Severe or chronic 
manifestations may need long term therapy for better 
results and to avoid recurrence. The study concludes that 
Pachana followed by Stambhana treatment is effective in 
Asrigdara along with Ama condition. Stambhana 
treatment alone works effectively when disease is in 
Nirama state. Hence, Pachana followed by Stambhana 
certainly provides a great cure in Rakta Pradara disease. 
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